# Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD

> **NCT02059434** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 55 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)
- Asthma

## Interventions

- **DRUG:** LAS190792 Dose 1
- **DRUG:** LAS190792 Dose 2
- **DRUG:** LAS190792 Dose 3
- **DRUG:** LAS190792 Dose 4
- **DRUG:** LAS190792 Dose 5
- **DRUG:** LAS190792 Dose 6
- **DRUG:** LAS190792 Dose 1 (Part 2)
- **DRUG:** LAS190792 Dose 2 (Part 2)
- **DRUG:** Tiotropium 18 μg
- **DRUG:** Indacaterol 150 μg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02059434
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-01
- **Primary completion:** 2014-10-06
- **Final completion:** 2014-10-06
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2019-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02059434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02059434, "Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02059434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*